Skip to main content
. 2021 Jul 23;9:698639. doi: 10.3389/fcell.2021.698639

FIGURE 4.

FIGURE 4

Inhibition of leukemia cell growth and metabolic activity by NK3.3-derived EV treatment in vitro. (A–H) Dose response analyses were performed using concentrations of EVs ranging from 1 to 100 μg/ml or PBS (0). Absorbance measurements using the WST-1 cell viability assay were assessed in K562 cells treated with either (A) HEK293 EVs or (B) NK3.3 EVs, and Jurkat cells treated with either (C) HEK293 EVs or (D) NK3.3 EVs. Mean absorbance ± SE; n = 3. Corresponding live cell counts, determined by automated cell counting using trypan blue dye exclusion, were performed at the same time as the WST-1 measurements for K562 cells treated with either (E) HEK293 EVs or (F) NK3.3 EVs, and Jurkat cells treated with either (G) HEK293 EVs or (H) NK3.3 EVs. Mean cell numbers ± SE; n = 3. p-Values determined by comparison of NK3.3 EV-treated cells at each treatment concentration to HEK293 EV-treated cells at the corresponding EV concentration. ∗p ≤ 0.05, ∗∗p ≤ 0.005, ∗∗∗p ≤ 0.0005.